Key result
Concomitant hypertension in HCM linked to ~32% higher all-cause mortality risk.
Why the study?
The CMR phenotype, mortality risk, and long-term prognostic performance of CMR-derived biomarkers in hypertrophic cardiomyopathy patients with concomitant hypertension remained to be characterized.
Does concomitant hypertension increase all-cause mortality in patients with hypertrophic cardiomyopathy?
Cohort (n=2,873)
Yes
Does concomitant hypertension increase all-cause mortality in patients with hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
In patients with hypertrophic cardiomyopathy, concomitant hypertension is associated with a distinct CMR phenotype and an increased risk of long-term all-cause mortality.
AIMS: To characterize the cardiovascular magnetic resonance (CMR) phenotype of hypertensive hypertrophic cardiomyopathy (HCM) patients, assess the association between hypertension and all-cause mortality, and compare the long-term prognostic performance of CMR-derived biomarkers between hypertensive versus non-hypertensive HCM patients. METHODS: Between 2008 and 2024, all consecutive HCM patients referred for CMR from the HCM-LGE registry were included. The primary outcome was all-cause mortality. Clinical variables, cardiac volumes, myocardial mass, functions and tissue characterization with late gadolinium enhancement (LGE) were assessed in all patients. The prognostic value of hypertension and CMR-derived biomarkers were assessed using survival analysis. RESULTS: Among 2,873 patients with HCM (52±8 years, 56% males), 796 (28%) had hypertension. Hypertensive HCM patients had greater LGE extent (1.1±1.8 vs 0.9±1.5, p<0.001), more LGE multiple locations (17% vs 11%, p<0.001), more midwall LGE (35% vs 28%, p=0.001). After propensity score matching 1:1, survival curves showed an increased risk of all-cause mortality for hypertensive HCM patients at median 9 year-follow up (HR: 1.32 [95% CI: 1.04-1.69]; log-rank p=0.024). High LGE extent >3 segments and septal location of LGE were independently associated with mortality in hypertensive HCM patients (HR: 3.99 [95%CI: 2.21-7.18]; p=<0.001 and HR: 1.76 [95%CI: 1.03-3.01]; p=0.039, respectively) and non-hypertensive HCM patients (HR: 4.63 [95%CI: 2.15-9.97]; p<0.001 and HR: 1.48 [95%CI: 1.02-2.15]; p=0.040, respectively). CONCLUSION: In a large multicenter cohort of HCM patients, concomitant hypertension was associated with increased long-term mortality and prognostic associations of CMR-LGE biomarkers were found. These findings highlight the importance of comprehensive cardiovascular risk assessment in HCM patients.
No takes yet. Share an insight, caveat, or question.
Florence et al. (2026) conducted a cohort in Hypertrophic cardiomyopathy (n=2,873). Hypertension vs. Non-hypertensive was evaluated on All-cause mortality (HR 1.32, 95% CI 1.04-1.69, p=0.024). Concomitant hypertension in patients with hypertrophic cardiomyopathy was associated with an increased risk of all-cause mortality (HR 1.32; 95% CI 1.04-1.69; p=0.024).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: